Macquarie Group Ltd. increased its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 0.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 25,969 shares of the biopharmaceutical company’s stock after purchasing an additional 197 shares during the quarter. Macquarie Group Ltd. owned 0.06% of Emergent Biosolutions worth $881,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Emergent Biosolutions by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after purchasing an additional 238,194 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Emergent Biosolutions by 7.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after purchasing an additional 152,029 shares during the last quarter. Aberdeen Asset Management PLC UK increased its position in shares of Emergent Biosolutions by 7.3% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock valued at $58,918,000 after purchasing an additional 118,894 shares during the last quarter. State Street Corp increased its position in shares of Emergent Biosolutions by 17.2% during the 1st quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after purchasing an additional 213,500 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of Emergent Biosolutions by 2.1% during the 2nd quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock valued at $32,505,000 after purchasing an additional 19,833 shares during the last quarter. 85.73% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on EBS shares. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $45.00.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction on Friday, September 29th. The stock was sold at an average price of $40.50, for a total value of $1,012,500.00. Following the sale, the chairman now owns 1,555,216 shares in the company, valued at $62,986,248. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald Richard sold 22,415 shares of Emergent Biosolutions stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $40.00, for a total value of $896,600.00. Following the completion of the sale, the director now owns 24,676 shares in the company, valued at approximately $987,040. The disclosure for this sale can be found here. Insiders sold 180,227 shares of company stock worth $6,993,970 in the last 90 days. Company insiders own 16.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Macquarie Group Ltd. Has $881,000 Stake in Emergent Biosolutions, Inc. (EBS)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://theolympiareport.com/2017/10/29/macquarie-group-ltd-has-881000-stake-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.60 on Friday. The company has a market cap of $1.67 billion, a P/E ratio of 25.86 and a beta of 1.26. The stock’s 50 day moving average price is $39.51 and its 200 day moving average price is $34.72. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $41.46.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million during the quarter, compared to analysts’ expectations of $111.57 million. During the same quarter in the prior year, the firm earned ($0.05) EPS. Emergent Biosolutions’s revenue for the quarter was up 10.4% compared to the same quarter last year. Analysts expect that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.